Morgan Stanley Maintains Equal-Weight on Pacific Biosciences, Lowers Price Target to $2
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Tejas Savant maintains an Equal-Weight rating on Pacific Biosciences (NASDAQ:PACB) but lowers the price target from $4 to $2.
August 12, 2024 | 5:34 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley analyst Tejas Savant maintains an Equal-Weight rating on Pacific Biosciences but lowers the price target from $4 to $2.
The lowered price target from $4 to $2 by Morgan Stanley suggests a negative outlook on Pacific Biosciences' stock performance, likely leading to a short-term decline in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100